DK1107746T3 - Anvendelsesmåder og sammensætninger omfattende dopamingenoptagelsesinhibitorer - Google Patents

Anvendelsesmåder og sammensætninger omfattende dopamingenoptagelsesinhibitorer

Info

Publication number
DK1107746T3
DK1107746T3 DK99945137T DK99945137T DK1107746T3 DK 1107746 T3 DK1107746 T3 DK 1107746T3 DK 99945137 T DK99945137 T DK 99945137T DK 99945137 T DK99945137 T DK 99945137T DK 1107746 T3 DK1107746 T3 DK 1107746T3
Authority
DK
Denmark
Prior art keywords
disorders
dopamine reuptake
disorder
desmethylsibutramine
didesmethylsibutramine
Prior art date
Application number
DK99945137T
Other languages
Danish (da)
English (en)
Inventor
Thomas P Jerussi
Qun K Fang
Chrisantha H Senanayake
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK1107746T3 publication Critical patent/DK1107746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Information Transfer Systems (AREA)
DK99945137T 1998-08-24 1999-08-23 Anvendelsesmåder og sammensætninger omfattende dopamingenoptagelsesinhibitorer DK1107746T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9766598P 1998-08-24 1998-08-24
US9930698P 1998-09-02 1998-09-02
US09/372,158 US6331571B1 (en) 1998-08-24 1999-08-11 Methods of treating and preventing attention deficit disorders
EP99945137A EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Publications (1)

Publication Number Publication Date
DK1107746T3 true DK1107746T3 (da) 2005-02-14

Family

ID=27378425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99945137T DK1107746T3 (da) 1998-08-24 1999-08-23 Anvendelsesmåder og sammensætninger omfattende dopamingenoptagelsesinhibitorer

Country Status (21)

Country Link
US (3) US6331571B1 (zh)
EP (2) EP1107746B1 (zh)
JP (1) JP2002523366A (zh)
KR (3) KR20010085553A (zh)
CN (1) CN100415222C (zh)
AT (1) ATE279184T1 (zh)
AU (2) AU772303B2 (zh)
CA (1) CA2341441C (zh)
CZ (1) CZ2001677A3 (zh)
DE (1) DE69921157T2 (zh)
DK (1) DK1107746T3 (zh)
ES (1) ES2226435T3 (zh)
HK (1) HK1088238A1 (zh)
HU (1) HUP0103408A3 (zh)
ID (1) ID28638A (zh)
IL (2) IL141531A0 (zh)
NO (1) NO20010943L (zh)
NZ (1) NZ510193A (zh)
PL (1) PL200264B1 (zh)
PT (1) PT1107746E (zh)
WO (1) WO2000010551A2 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
JP2003519087A (ja) * 1999-03-19 2003-06-17 クノール・ゲー・エム・ベー・ハー 摂食障害を治療する方法
SK286669B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) * 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DE60229123D1 (de) * 2001-02-20 2008-11-13 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
US20040197397A1 (en) * 2002-08-30 2004-10-07 Watson Pharmaceuticals, Inc. Drug delivery system for treatment of urinary incontinence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050228052A1 (en) * 2004-01-29 2005-10-13 Barberich Timothy J Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
DK1742624T3 (da) * 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
KR100618176B1 (ko) * 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
WO2006067060A2 (en) * 2004-12-22 2006-06-29 Ciba Specialty Chemicals Holding Inc. Enantioselective synthesis of a sterically hindered amine
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
WO2006073292A1 (en) * 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100632470B1 (ko) * 2005-02-25 2006-10-12 민연식 결정성 시부트라민 캄실레이트염과 이의 제조방법
BRPI0610780A2 (pt) * 2005-04-22 2016-09-06 Teva Pharma formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
CA2612268A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
WO2007106423A2 (en) * 2006-03-10 2007-09-20 The Research Foundation Of State University Of New York Tropane prodrugs with central nervous system activity
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
SG178775A1 (en) * 2007-02-12 2012-03-29 Dmi Biosciences Inc Reducing side effects of tramadol
MX2009008491A (es) * 2007-02-12 2010-01-20 Dmi Biosciences Inc Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.
US20110244059A1 (en) * 2008-08-20 2011-10-06 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113908295B (zh) * 2021-11-12 2023-07-21 郑州大学第一附属医院 一种阿普唑仑包合物及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (de) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
JPS5940638A (ja) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd 直接ポジ用ハロゲン化銀写真乳剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69318196T2 (de) 1992-01-28 1998-08-27 Fujitsu Ltd Plasma Farbanzeige-Vorrichtung von Oberflächenentladungs-Typ
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
AU4542893A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1994000047A1 (en) 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
JP3823194B2 (ja) 1994-09-19 2006-09-20 アステラス製薬株式会社 ５ｈｔ▲３▼拮抗剤の新規医薬用途
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction

Also Published As

Publication number Publication date
IL141531A (en) 2010-05-31
CZ2001677A3 (cs) 2002-02-13
PL346843A1 (en) 2002-02-25
KR20010085553A (ko) 2001-09-07
ES2226435T3 (es) 2005-03-16
JP2002523366A (ja) 2002-07-30
HK1088238A1 (en) 2006-11-03
NO20010943D0 (no) 2001-02-23
HUP0103408A3 (en) 2002-10-28
US6331571B1 (en) 2001-12-18
US20030195261A1 (en) 2003-10-16
AU772303B2 (en) 2004-04-22
IL141531A0 (en) 2002-05-23
US6538034B2 (en) 2003-03-25
CA2341441A1 (en) 2000-03-02
PT1107746E (pt) 2005-03-31
KR20080011354A (ko) 2008-02-01
ATE279184T1 (de) 2004-10-15
AU5781799A (en) 2000-03-14
WO2000010551A3 (en) 2000-09-21
CN100415222C (zh) 2008-09-03
NZ510193A (en) 2003-09-26
KR100887008B1 (ko) 2009-03-04
ID28638A (id) 2001-06-21
EP1475086A2 (en) 2004-11-10
HUP0103408A2 (hu) 2002-05-29
EP1107746A2 (en) 2001-06-20
AU2004200875A1 (en) 2004-04-01
US20020188029A1 (en) 2002-12-12
DE69921157T2 (de) 2006-02-02
WO2000010551A2 (en) 2000-03-02
CN1735407A (zh) 2006-02-15
DE69921157D1 (de) 2004-11-18
NO20010943L (no) 2001-04-23
EP1475086A3 (en) 2006-12-13
KR20060081725A (ko) 2006-07-13
PL200264B1 (pl) 2008-12-31
CA2341441C (en) 2011-07-19
EP1107746B1 (en) 2004-10-13
US7071234B2 (en) 2006-07-04
AU2004200875B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
DK1107746T3 (da) Anvendelsesmåder og sammensætninger omfattende dopamingenoptagelsesinhibitorer
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
JP2003524613A5 (zh)
RU2009138602A (ru) Новые производные бензазепина
CA2352324A1 (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
JP2007517059A5 (zh)
TW200635589A (en) Therapeutic agents
JPH09505585A (ja) 酸化窒素合成の誘導を遮断するためのテトラヒドロビオプテリン利用の遮断
RU2005141060A (ru) Метаболит кветиапина
NZ597498A (en) Cyclopropyl amine derivatives as histamin H3 receptor modulators
NO20041060L (no) Krystaller av hydroksynorefedrinderivat
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
US20040266864A1 (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
WO2008018639A3 (en) Glycine transporter inhibitor
JP2004529936A5 (zh)
RU2010114206A (ru) N-ОКСИДЫ ОКТАГИДРОПИРРОЛО[3,4-b]ПИРРОЛА
WO2004071152A3 (en) Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
MX2023000437A (es) Derivado de bencisoxazol.
ATE423093T1 (de) Neue mao-b-hemmer
MX2008012212A (es) Metodos para tratar trastornos cognitivos y otros afines.
WO2003014114A3 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
Koran Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder
RU2010107460A (ru) (2s, 3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения